31
Participants
Start Date
May 17, 2015
Primary Completion Date
October 16, 2017
Study Completion Date
October 16, 2017
Entecavir
Entecavir will be administered as per local labeling.
Placebo
Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
RO6864018
Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
Tenofovir
Tenofovir will be administered as per local labeling.
Taipei Veterans General Hospital, Taipei
Kaohsiung Medical Uni Chung-Ho Memorial Hospital; Dept of Internal Medicine, Kaohsiung City
Auckland Clinical Studies Limited, Grafton
Waikato Hospital, Hamilton
National Taiwan University Hospital, Taipei
University Malaya Medical Center, Kuala Lumpur
Hospital Ampang, Ampang
Hospital Selayang; Medicine, Batu Caves
Changi General Hospital, Singapore
Queen Mary Hospital, Hong Kong
Prince of Wales Hospital; Special Medical Clinic, N.T.
Seoul National University Hospital, Seoul
Severance Hospital, Yonsei University Health System, Seoul
Asan Medical Center, Seoul
Hoffmann-La Roche
INDUSTRY